HCA Healthcare

HCA

402.5901.72% ( +6.800 )

Closed: Jul 31, 16:00:00 (EDT)

HCA Healthcare

HCA

402.5901.72% ( +6.800 )

Closed: Jul 31, 16:00:00 (EDT)

2026-W302026-07-20

HCA.US Weekly Report · 2026-W30

Overview

HCA Healthcare released Q2 2026 earnings this week, showing revenue growth of 8.7% year-over-year but a significant slowdown in profit expansion. Management trimmed full-year EPS guidance citing payer mix headwinds and reduced surgical volumes. The stock rebounded from 371 to 382, a weekly gain of 3%, though all three investor categories (institutional, retail) displayed net outflows. While analyst ratings remain constructive, the guidance reduction has exposed the lag in institutional forecasts.

Price Action

Weekly return: +2.97% (closing at 382.19 vs. prior Friday close of 371.18)

Weekly trading range showed volatility: high-low spread of 22.52, representing 5.91% of opening price. Volume averaged 1.35M shares daily, roughly in line with recent norms. The week displayed a V-shaped recovery—modest decline through Tuesday, then sustained rally from Wednesday onward. Earnings release day (Thursday) opened gapped-up to 381, closing at 382 on a small bullish candle.

Valuation

P/E multiple of 12.58x sits in the lower quintile (30th percentile) over the trailing one-year period, indicating undervaluation. Industry median P/E stands at 10.41x; HCA trades slightly above peer average but remains cheap on an absolute basis. P/B is deeply negative (-13.56), reflecting negative shareholder equity from historical leverage and share buybacks.

Earnings vs. Consensus

Q1 2026 actuals:

EPS: 7.15, YoY +10.85%
Revenue: 19.109B, YoY +4.3%
Net income: 1.62B, YoY +0.62%
Operating income: 2.863B, YoY +0.28%

A critical mismatch: revenue growth (4.3%) far outpaces profit growth (0.62%), signaling margin compression. Post-earnings, institutional consensus for 2026 full-year EPS is 31.054 (median 31.026), yet management trimmed guidance, implying pressure ahead. This disconnect between revenue expansion and bottom-line delivery is the core concern.

Capital Flow

All three investor tiers showed net redemptions this week:

Institutional: net outflow (inflow 337 vs. outflow 1,202)
Mid-cap: net outflow (inflow 1,773 vs. outflow 2,105)
Retail: net outflow (inflow 3,008 vs. outflow 5,087)

Despite 13 buy ratings and 10 hold ratings (52% + 40% conviction), actual capital is flowing out. This divergence signals skepticism about the execution path—a sign that analyst ratings may lag the market’s assessment of profit risks.

Institutional Ratings

Coverage universe: 25 analysts

13 Buy (52%)
10 Hold (40%)
1 Reduce (4%)

Average price target: 467.2, implying 22.2% upside from current levels. Last updated July 24, 2026. Important caveat: most ratings predate the Q2 guidance cut; expect downgrades to follow.

Weekly News Highlights

This week’s narrative revolves around Q2 earnings—a baseline of solid revenue growth overshadowed by margin erosion and forward guidance trimming.

Key Stories (reverse chronological)

Takeaway

HCA delivered the classic “beat and trim” earnings: solid revenue (up 8.7%) masked by profit deceleration and forward guidance cuts. With net profit up just 0.62% despite 4.3% revenue growth, margin pressure from payer mix and surgical volume is real and material. Valuation sits cheap (P/E at 30th percentile), but three-way net outflows suggest the market has not yet fully repriced downside risks. Analyst ratings remain constructive but are likely to lag; the next catalyst is management’s execution against the trimmed guidance in H2 2026.